Cargando…
BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis
BACKGROUND: Intravesical immunotherapy with Mycobacterium bovis bacillus Calmette-Guérin has been established as the most effective adjuvant treatment for high risk non-muscle-invasive bladder cancer (NMIBC). We investigated the differences between the S4-Jena BCG strain and commercially available B...
Autores principales: | Schwarzer, Katja, Foerster, Martin, Steiner, Thomas, Hermann, Inge-Marie, Straube, Eberhard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908063/ https://www.ncbi.nlm.nih.gov/pubmed/20587032 http://dx.doi.org/10.1186/1475-2867-10-21 |
Ejemplares similares
-
Draft Genome Sequence of the Vaccination Strain Mycobacterium bovis BCG S4-Jena
por: Wibberg, Daniel, et al.
Publicado: (2016) -
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Genome Sequencing and Analysis of BCG Vaccine Strains
por: Zhang, Wen, et al.
Publicado: (2013) -
Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017) -
BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)